Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.

NCT ID: NCT03497377

Last Updated: 2020-05-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-05-16
• Study Completion Date: 2020-04-30

Brief Summary

The objective of this study is to evaluate a radiolabeled urea-based small molecule inhibitor of prostate-specific membrane antigen (PSMA), [18F]DCFPyL (DCFPyL) PET/CT (or PET/MRI imaging if available) for detection of metastatic prostate cancer. PSMA is a well characterized histological marker of prostate cancer tumor aggressiveness and metastatic potential. Preliminary first-in-human studies demonstrate high specific uptake of a first generation less avid compound, DCFBC, in metastatic prostate cancer and demonstrated feasibility for prostate cancer metastatic detection. Investigators propose to assess the ability of DCFPyL PET to detect metastatic prostate cancer by visual qualitative and quantitative SUV analysis. Correlation will be made to sites of suspected metastatic disease detected by ultra sensitive but less specific [18F]Sodium Fluoride (NaF)-PET/CT imaging for prostate cancer.

Conditions

Metastatic Prostate Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

18F-DCFPyL Injection & 18F-NaF

A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL injected by slow IV push. A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose

Group Type: EXPERIMENTAL

18F-DCFPyL Injection

Intervention Type: DRUG

18F-NaF

Intervention Type: DRUG

Interventions

18F-DCFPyL Injection

Intervention Type: DRUG

18F-NaF

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Histological confirmation of prostate cancer

2. Radiologic evidence of new or progressive metastatic disease demonstrated on anatomical imaging (CT, MRI, or ultrasound), bone scintigraphy, [18F]Sodium Fluoride PET, and/or [18F]FDG PET

3. Rising PSA on two observations taken at least 1 week apart

4. Adequate peripheral venous access or available central venous catheter access for radiopharmaceutical administration

5. Patient can remain on androgen deprivation therapy if on the same regimen prior to documentation of progressive metastatic disease

6. Patient cannot start a new therapy for prostate cancer prior to study radiopharmaceutical imaging

7. Patient is judged by the Investigator to have the initiative and means to be compliant with the protocol and be within geographical proximity to make the required study visits

8. Patients or their legal representatives must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures

Exclusion Criteria

1. Patient has been treated with an investigational drug, investigational biologic, or investigational therapeutic device within 14 days prior to study radiotracer administration

2. Prior radiation therapy, chemotherapy, or androgen-deprivation therapy within 2 weeks prior to study radiotracer administration (Washout is one half-life of the drug or 2 weeks, whichever is longest)

3. Initiation of new therapy for progressive metastatic disease since radiographic documentation of progression.

4. Serum creatinine > 3 times the upper limit of normal

5. Total bilirubin > 3 times the upper limit of normal

6. Liver Transaminases > 5times the upper limit of normal

7. Unable to lie flat during or tolerate PET/CT (or PET/MRI imaging if available)

8. Prior history of any other malignancy within last 2 years, other than skin basal cell carcinoma or superficial bladder cancer.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Martin Pomper, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Nuclear Medicine

Locations

Johns Hopkins University

Baltimore, Maryland, United States

Countries

United States

Other Identifiers

J1559

Identifier Type: -

Identifier Source: org_study_id

IRB00065679

Identifier Type: OTHER

Identifier Source: secondary_id

1U01CA183031-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link